Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDKN2A loss |
Therapy | Milciclib |
Indication/Tumor Type | brain glioblastoma multiforme |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A loss | brain glioblastoma multiforme | sensitive | Milciclib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Milciclib (PHA-848125AC) resulted in tumor regression in glioma cell line xenograft models with CDKN2A loss (PMID: 23347136). | 23347136 |
PubMed Id | Reference Title | Details |
---|---|---|
(23347136) | Anti-tumour efficacy on glioma models of PHA-848125, a multi-kinase inhibitor able to cross the blood-brain barrier. | Full reference... |